Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 7th
August 01 2014 - 7:30AM
Business Wire
Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration
company focused on advanced wound care, announced today that it
will hold a conference call on August 7, 2014 to discuss the
financial results for the second quarter of 2014. In addition,
management will provide a business update and a discussion on
recent and upcoming milestones.
The conference call is scheduled to begin at 11:00 a.m. (Eastern
Time). The results will be released before the opening of the
market that same day.
To access the conference call, U.S.-based listeners should dial
888-563-6275 and international listeners should dial 706-634-7417.
All listeners should provide the following passcode: 82860672.
Individuals interested in listening to the live conference call via
the Internet may do so by logging on to the Company’s website at
www.dermasciences.com.
Following the conclusion of the conference call, a replay will
be available through August 13, 2014 and can be accessed by dialing
(855) 859-2056 from within the U.S. or (404) 537-3406 from outside
the U.S. All listeners should provide passcode 82860672. The
webcast will be available for 30 days.
About Derma Sciences, Inc.
Derma Sciences is a tissue regeneration company focused on
advanced wound and burn care. It offers a line of products with
patented technologies to help better manage chronic and
hard-to-heal wounds, many of which result from diabetes and poor
vascular functioning. The company recently entered the $500 million
market for skin substitute products with its licensing of
AMNIOEXCEL® and AMNIOMATRIX® in the first quarter of 2014.
AMNIOEXCEL® has been launched to customers and the Veterans
Administration recently has included the product in its Federal
Supply Schedule V797P-2000D. Derma Sciences’ MEDIHONEY® product is
the leading brand of honey-based dressings for the management of
wounds and burns. The product has been shown in clinical studies to
be effective in a variety of indications. TCC-EZ® is its
gold-standard total contact casting system for diabetic foot
ulcers. Other novel products introduced into the $14 billion global
wound care market include XTRASORB® for better management of wound
exudate, and BIOGUARD® for barrier protection against microbes and
other contaminants. Its pharmaceutical wound care products include
DSC127, which is currently in Phase 3 clinical trials for the
healing of diabetic foot ulcers. The drug candidate is also part of
a BARDA grant program for the healing/prevention of tissue damage
due to ionizing radiation exposure. The patented API peptide used
in DSC127 is also in preclinical testing for scar
prevention/reduction. The company also offers a full product line
of traditional dressings.
For more information please visit www.dermasciences.com.
Derma Sciences, Inc.John
Yetter, 609-514-4744Chief Financial
Officerjyetter@dermasciences.comorLHAKim Sutton Golodetz,
212-838-3777kgolodetz@lhai.comOrBruce Voss,
310-691-7100bvoss@lhai.com
Derma Sciences, Inc. (NASDAQ:DSCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Derma Sciences, Inc. (NASDAQ:DSCI)
Historical Stock Chart
From Apr 2023 to Apr 2024